Michael Buschle
Director/Board Member at VICORE PHARMA HOLDING AB
Network origin in Michael Buschle first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 16 | |
HBM Partners AG
 HBM Partners AG Investment ManagersFinance HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US.
15
| Private Company | Investment Managers | 15 |
| Public Company | Pharmaceuticals: Major | 5 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Michael Buschle via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| CHEMOCENTRYX, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Top Institute Pharma
 Top Institute Pharma BiotechnologyHealth Technology Part of Center for Translational Molecular Medicine, Top Institute Pharma provides pharmaceutical research services. The private company is based in Leiden, Netherlands. Top Institute Pharma was acquired by Center for Translational Molecular Medicine on June 09, 2015. | Biotechnology | Director/Board Member | |
HealthCap AB
 HealthCap AB Investment ManagersFinance HealthCap AB (HealthCap) is a venture capital subsidiary of Odlander, Fredrikson & Co. AB founded in 1995 by Björn Ingemar Odlander and Peder Fredrikson. The firm is headquartered in Stockholm, Sweden with an additional office in Switzerland. | Investment Managers | Private Equity Investor Private Equity Investor | |
| Karolinska Institutet | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
| HBM HEALTHCARE INVESTMENTS AG | Investment Managers | Chief Executive Officer Director of Finance/CFO | |
| University of Michigan | College/University | Undergraduate Degree Undergraduate Degree | |
| University of Uppsala | College/University | Corporate Officer/Principal Graduate Degree Graduate Degree | |
ESBATech, a Novartis Co. GmbH
 ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Vicore Pharma AB
 Vicore Pharma AB Pharmaceuticals: MajorHealth Technology Vicore Pharma AB researches and develops pharmaceutical products. The company is headquartered in Gothenburg, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
| University of Lund | College/University | Graduate Degree Doctorate Degree Undergraduate Degree | |
| University of Utrecht | College/University | Doctorate Degree | |
| University of Zurich | College/University | Doctorate Degree | |
| Swiss Federal Institute of Technology | College/University | Doctorate Degree Doctorate Degree | |
| University of Gothenburg | College/University | Doctorate Degree Doctorate Degree | |
| BONESUPPORT HOLDING AB | Medical Specialties | Corporate Officer/Principal | |
Genzyme Europe BV
 Genzyme Europe BV Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Europe BV is a Dutch company that develops and manufactures pharmaceutical and biotherapeutic products. The private company is based in Amsterdam, Netherlands. | Pharmaceuticals: Major | Sales & Marketing | |
| Organon International BV | President | ||
| BIOATLA, INC. | Biotechnology | Director/Board Member | |
Neurelis, Inc.
 Neurelis, Inc. Pharmaceuticals: MajorHealth Technology Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Director/Board Member | |
HBM Healthcare Investments (Cayman) Ltd.
 HBM Healthcare Investments (Cayman) Ltd. Hospital/Nursing ManagementHealth Services Part of HBM Partners AG, HBM Healthcare Investments (Cayman) Ltd. provides healthcare services. The private company is based in George Town, Cayman Islands. Andreas Wicki has been the CEO of the company since 2001. | Hospital/Nursing Management | Chief Executive Officer Director/Board Member Director/Board Member | |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
HBM Partners AG (Investment Management)
 HBM Partners AG (Investment Management) Investment ManagersFinance HBM Partners AG (Investment Management) (HBM-IM) is the asset management division of HBM Partners AG. The firm is headquartered in Zug and was founded in 2001. HBM-IM provides investment advisory services to private companies. They manage the fund HBM Healthcare Investments. | Investment Managers | Chief Executive Officer Portfolio Manager-Equities Analyst-Equity Portfolio Manager-Equities | |
| OBSEVA SA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| WILSON THERAPEUTICS AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
HealthCap Advisor AB
 HealthCap Advisor AB Investment ManagersFinance HealthCap Advisor AB provides investment advice. The private company is based in Stockholm, Sweden. | Investment Managers | Corporate Officer/Principal | |
| PHARVARIS N.V. | Pharmaceuticals: Major | Founder Director/Board Member | |
Vitaeris, Inc.
 Vitaeris, Inc. BiotechnologyHealth Technology Vitaeris, Inc. develops new treatment options for chronic inflammatory diseases. The company was founded by Kevin Chow, Patrick A. Robinson and Noel F. Hall in 2016 and is headquartered in Vancouver, Canada. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
| Healthcap Aero Holdings Gp | Director/Board Member | ||
Trimb Holding AB
 Trimb Holding AB Financial ConglomeratesFinance Part of Karo Healthcare AB, Trimb Holding AB operates as a holding Swedish company with interest in pharmaceuticals. The private company is based in Stockholm, Sweden. | Financial Conglomerates | Director/Board Member | |
Skipjack AB
 Skipjack AB Real Estate DevelopmentFinance Skipjack AB Manages real properties. The company is headquartered in Stockholm, Sweden. | Real Estate Development | Director/Board Member | |
Swixx Biopharma SA
 Swixx Biopharma SA Miscellaneous Commercial ServicesCommercial Services Swixx Biopharma SA provides marketing and sales, regulatory, medical affairs, cold chain, logistic services to pharmaceutical companies. Its services also include receivables, collection, FX coverage, risk management, compliance, and reimbursement and market access. The company was founded by Petr Nemec and Robert Stuart Swanson in 2013 and is headquartered in Baar, Switzerland. | Miscellaneous Commercial Services | Corporate Officer/Principal Director/Board Member | |
CTx Operations, Inc.
 CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | Biotechnology | Director/Board Member | |
Healthcap Annex Fund I-Ii Bis Gp AB
 Healthcap Annex Fund I-Ii Bis Gp AB Financial ConglomeratesFinance Healthcap Annex Fund I-Ii Bis Gp AB operates as an investment holding Swedish company. The private company is based in Stockholm, Sweden. | Financial Conglomerates | Director/Board Member | |
INIM Pharma AB
 INIM Pharma AB Pharmaceuticals: MajorHealth Technology INIM Pharma AB operates as drug development company that focuses on the development of immunomodulatory drugs for interstitial lung diseases. It develops a new local treatment for severe rare lung diseases such as idiopathic pulmonary fibrosis. The company was founded by Carl-Johan Dalsgaard and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Chairman Director/Board Member Director/Board Member | |
| EllAug AB | Director/Board Member | ||
| GALECTO, INC. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
| ITEOS THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Synox Therapeutics Ltd.
 Synox Therapeutics Ltd. BiotechnologyHealth Technology Synox Therapeutics Ltd. a clinical stage biopharmaceutical company. The company is headquartered in Dublin, Ireland. | Biotechnology | Director/Board Member | |
Tribune Therapeutics AB
 Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020. | Miscellaneous Commercial Services | Director/Board Member | |
| Mips Helmet AB | Director/Board Member | ||
Disruptive Pharma AB
 Disruptive Pharma AB Pharmaceuticals: MajorHealth Technology Disruptive Pharma AB is a pharmaceutical company based in Uppsala, Sweden, with a passion for innovation in drug products. The Swedish company has perfected the groundbreaking mesoporous magnesium carbonate (mmc) drug delivery technology, which makes it easier to develop amorphous drug candidates. By combining the mmc formulation technology with drug compounds, they can enhance existing products or assist in formulating new therapies. Disruptive Pharma seeks commercial partnership or licensing to industry partners within the drug improvement business area. The company was founded in 2018 by Maria Strömme, and the CEO is Peter Åsberg. | Pharmaceuticals: Major | Director/Board Member | |
| IO BIOTECH, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Mahzi Therapeutics, Inc.
 Mahzi Therapeutics, Inc. BiotechnologyHealth Technology Mahzi Therapeutics is a private biotechnology company that focuses on genetic therapies for rare genetic neurodevelopmental disorders. The company was founded by Yael Weiss and is based in San Mateo, CA. The company unites patient and family groups, academic researchers, diagnostic companies, other industry members, and its internal team of experts to develop therapies for patients with these serious diseases. Mahzi's team is experienced in all aspects of biopharmaceutical research, development, and manufacturing and is driven to make a difference in the lives of patients with rare genetic diseases. Yael Weiss has been the CEO since incorporation. | Biotechnology | Director/Board Member | |
| Aurelia Invest AB | Director/Board Member | ||
AdrenoMed AG
 AdrenoMed AG Pharmaceuticals: MajorHealth Technology AdrenoMed AG develops a drug to decrease mortality in severe sepsis. The company was founded by Bernd Wegener, Gerald Heinz Möller and Andreas Bergmann in 2009 and is headquartered in Berlin, Germany. | Pharmaceuticals: Major | Director/Board Member |
Statistics
International
| Sweden | 22 |
| United States | 11 |
| Switzerland | 8 |
| Netherlands | 7 |
| Cayman Islands | 2 |
Sectoral
| Health Technology | 24 |
| Finance | 9 |
| Consumer Services | 9 |
| Commercial Services | 5 |
| Health Services | 2 |
Operational
| Director/Board Member | 195 |
| Corporate Officer/Principal | 55 |
| Independent Dir/Board Member | 53 |
| Doctorate Degree | 22 |
| Chairman | 20 |
Most connected contacts
| Insiders | |
|---|---|
| James Healy | 50 |
| Jacob Uno Stanley Gunterberg | 33 |
| David Gill | 32 |
| Johannes G. C. P. Schikan | 22 |
| Chandra Paul Leo | 22 |
| Andreas Wicki | 21 |
| Carl-Johan Dalsgaard | 21 |
| Alexander G. Asam | 18 |
| Thomas Thaler | 17 |
| Bertil Lindmark | 14 |
| Gérard Ber | 12 |
| Michael Jasulavic | 12 |
| Margareta Elisabeth Björk | 12 |
| Priyanka Belawat | 10 |
| Heidi Hunter | 9 |
- Stock Market
- Insiders
- Michael Buschle
- Company connections
